Erratum: Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment.

[This corrects the article on p. 23 in vol. 60, PMID: 36911568.].

Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment.

Introduction: Fingolimod is the first oral immunomodulatory treatment used as secondary care therapy in the treatment of multiple sclerosis for the last 10 years. The objective of our study is to reveal the experiences of the first generic fingolimod active ingredient treatment in different centers across Turkey. Method: The first generic fingolimod efficacy and safety data of patients followed-up in 29 different clinical multiple sclerosis units in Turkey were analyzed retrospectively. Data regarding efficacy and safety of the patients were transferred to the data system both before the treatment and on the 6th, 12th and 24th month following the treatment. The data were analyzed using the IBM SPSS 20.00. P value of <0.05 was considered to be statistically significant. Results: A total of 508 multiple sclerosis patients, 331 of whom were women, were included in the study. Upon comparing the Expanded Disability Status values before and after the treatment, a significant decrease was observed, especially at month 6 and thereafter. Since bradycardia occurred in 11 of the patients (2.3%), the first dose had to be longer than 6 hours. During the observation of the first dose, no issues that could prevent the use of the drug occured. Side effects were seen in 49 (10.3%) patients during the course of fingolimod treatment. Respectively, the most frequent side effects were bradycardia, hypotension, headache, dizziness and tachycardia. Conclusion: The observed results regarding efficacy and safety were similar to clinical trial data in the literature and real life data in terms of the first equivalent with fingolimod active ingredient.

The neurotoxic effects of prenatal gabapentin and oxcarbazepine exposure on newborn rats.

AIM: Teratogenicity is a problematic issue for pregnant women because of X-ray radiation, drugs, and genetic and unknown variables. First-generation antiepileptic drugs (AED) like valproic acid are well-known teratogens for developing fetuses. However, their usage is necessary in order to prevent maternal seizures. The underlying mechanism of birth defects associated with AED exposure remains unclear and information about the neurotoxic effects of prenatal exposure to AED is still limited. Oxcarbazepine (OXC) and gabapentin (GBP) are second-generation AED. It still remains unclear how much these drugs are safe during pregnancy. This study aimed to investigate whether any neurotoxic effect of OXC and GBP in utero exposure on the developing brain. METHODS: Eighteen pregnant Wistar albino rats were divided into six groups. The first group was exposed to OXC at 100 mg/kg/day, the second to GBP at 50 mg/kg/day, and third to saline (0.9% NaCl) at 1.5 ml/day between the first and the fifth days of gestation. The same procedure was applied at the same dosages between the 6th and the 15th days of gestation for the 2nd three groups. Five female offspring (total n = 30, 45 days old) were taken from each group and stereological methods were applied in order to analyze the total and dopaminergic neuron number of the substantia nigra pars compacta (SNc). CONCLUSION: The result is that the OXC and GBP exposure at different gestational periods may not give rise to congenital malformation and it appears that the GBP exposure during the organogenesis period proliferatively affects the total number of neurons.

The relationship of illness perceptions with demographic features, pain severity, functional capacity, disability, depression, and quality of life in patients with chronic low back pain.

OBJECTIVES: The aim of this study was to evaluate the relationship of illness perceptions (IPs) with demographic features, severity of pain, functional capacity, disability, depression, and quality of life in patients with chronic low back pain (CLBP). PATIENTS AND METHODS: Between January 2015 and July 2015, a total of 114 patients with non-specific CLBP (86 females, 28 males; mean age 47.1±15.2 years; range, 18 to 85 years) were included. Non-specific CLBP was defined as low back pain not attributable to a recognizable, known specific pathology such as infection, tumor, inflammation for ≥12 weeks. The IPs using the revised Illness Perception Questionnaire (IPQ-R), pain severity using the visual analog scale (VAS), functional capacity using the Six-Minute Walk Test (6MWT), disability using the modified Oswestry Disability Index (m-ODI), depression using the Beck Depression Inventory (BDI), and quality of life using the Short Form-36 (SF-36) were assessed. RESULTS: There was a significant, positive correlation between the age, body mass index, duration of disease, pain scores, and IPQ-R- consequences, timeline (acute/chronic), and emotional responses subunits, whereas there was a significant, negative correlation between the IPQ-R-personal and treatment control subunits (p<0.001). The IPQ-R-timeline (acute/chronic), consequences, and emotional response subunits were positively and personal and treatment controls and illness coherence subunits were negatively correlated with the BDI and m-ODI (p<0.001). The IPQ-R-consequences and emotional responses subunits were negatively and timeline (acute/chronic), personal and treatment controls, and illness coherence subunits were positively correlated with the SF-36 subunits (p<0.05). CONCLUSION: The IPs were negatively affected by advanced age, high body mass index, longer duration of disease, and increased severity of pain in CLBP patients. Based on these findings, positive IPs may be related with reduced disability and depression, and improved quality of life and functional capacity in this patient population. Developing new strategies for improving the negative IPs of patients with CLBP may be useful.

Reliability and Validity of Turkish Version of Short Form of the Social Role Participation Questionnaire in Patients With Ankylosing Spondylitis.

OBJECTIVES: This study aims to evaluate the reliability and validity of the Turkish version of the Short Form of the Social Role Participation Questionnaire (s-SRPQ) in Turkish patients with ankylosing spondylitis. PATIENTS AND METHODS: The Turkish version of s-SRPQ questionnaire was obtained after a translation and back translation process. The study sample included 100 ankylosing spondylitis patients (59 males, 41 females; mean age 42.0±11.0 years; range 19 to 69 years). To assess the test-retest reliability of the Turkish s-SRPQ, the questionnaire was reapplied 15 days after the first interview (interclass correlation coefficient [ICC]). Cronbach's alpha (a) was used to evaluate the internal consistency. The s-SRPQ was compared with Short Form-36 (SF-36) survey, Ankylosing Spondylitis Quality of Life questionnaire (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), and Satisfaction With Life Scale (SWLS) for convergent validiy. RESULTS: For s-SRPQ/experienced physical difficulties; the individual item ICC ranged from 0.78 to 1.00 and Cronbach's alpha value ranged from 0.88 to 1.00. For s-SRPQ/satisfaction with role performance; the individual item ICC ranged from 0.93 to 0.98 and Cronbach's alpha value ranged from 0.96 to 0.99. The Turkish version of s-SRPQ/experienced physical difficulties scores correlated with the SWLS and SF-36 sub-parameters negatively; and Ankylosing Spondylitis Disease Activity Index, and BASFI, and ASQoL positively. The SRPQ/satisfaction with role performance scores correlated with the SWLS and SF-36 sub-parameters positively; and BASDAI, and BASFI, and ASQoL negatively. CONCLUSION: Turkish version of s-SRPQ has good comprehensibility, internal consistency, and validity and is an adequate and useful instrument for the assessment of participation in Turkish patients with ankylosing spondylitis.

Plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in Behçet's disease and correlation with disease activity.

BACKGROUND: Soluble urokinase plasminogen activator receptor (suPAR), a new biomarker, is a soluble form of membrane-bound receptors secreted from different immune cells. The aim of the present study is to determine plasma suPAR levels in Behçet's disease and their correlation with disease activity. METHODS: Thirty Behçet's disease patients determined according to the International Study Group criteria for Behçet's disease diagnosis and 41 healthy subjects were included in the present study. Micro-enzyme-linked immunosorbent assay was employed to obtain quantitative data. Data of both groups were statistically analyzed. RESULTS: The comparison of C-reactive protein and suPAR plasma levels of the control and Behçet's disease group revealed statistically significant differences (respectively, P = 0.003 < 0.05 and P = 0.020 < 0.05). However, plasma suPAR levels related with disease activity revealed no statistically significant differences (P > 0.05). CONCLUSION: The present study is the first study analyzing suPAR levels in Behçet's disease patients and their correlation with disease activity. However, further prospective studies with larger patient series using suPAR as a new plasma biomarker are required to diagnose and monitor Behcet's disease and to support the findings of the present study.

The Role of Real-Time Sonoelastography in the Differentiation of Benign From Malignant Parotid Gland Tumors.

OBJECTIVE: The aims of this study are to evaluate the utility of sonoelastography for parotid gland masses and to determine which cutoff strain ratio (SR) would be best for the differentiation between benign and malignant lesions. METHODS: From August 2015 to December 2016, 39 parotid gland masses were examined prospectively by ultrasonography and strain sonoelastography. Elastographic scores were determined by a 4-point scoring method. Interventional procedures were performed on all patients after sonographic examinations. The lesions were divided into groups as benign or malignant according to histopathological findings. The difference in elastographic scores between benign and malignant masses was evaluated. RESULTS: Among the 39 parotid gland masses, 33 (84.6%) were benign and 6 (15.3%) were malignant tumors with 53.8% (n = 21) of the lesions being on the right side. Pleomorphic adenoma (41%) was the most common neoplasm followed by Warthin tumor (28.2%). The median elastographic score was 2 (range, 1-3) for benign tumors, and it was 3 (range, 2-4) (P = 0.003) for malignant tumors. Median SR was 1.11 (range, 0.26-2.15), and it was 2.75 (range, 1.03-3.54) (P = 0.01) for benign and malignant tumors. In the receiver operating characteristic analysis, the cutoff value of the SR was 2.1, sensitivity was 83.3%, specificity was 97%, positive predictive value was 83.3%, negative predictive value was 97%, and accuracy was 94%. CONCLUSIONS: There was a statistically significant difference between benign lesions and malignant lesions in both elastography score and SR. It is possible that elastography can improve the noninvasive diagnostic accuracy for certain pathological conditions.

Radiological, clinical and audiological evaluation of jugular bulb-vestibular aqueduct dehiscence.

OBJECTIVE: The aim of this study is to determine the prevalence of jugular bulb-vestibular aqueduct dehiscence (JBVAD) in patients undergoing temporal bone multidetector computed tomography (MDCT) and assess the relationship between JBVAD and hearing loss with the findings of audiometry. METHODS: About 1503 temporal bone MDCT scans were evaluated for the prevalence of JBVAD. Correlation of the imaging findings and audiometric data was performed. Patients were divided into two groups, those with and those without hearing loss, and were statistically compared. RESULTS: Jugular bulb-vestibular aqueduct dehiscence was detected in 124 of the 1503 patients with a prevalence of 8.2%. MDCT images of 56 of the 124 patients were normal except for JBVAD (n = 38) and close proximity of the jugular bulb (JB) and vestibular aqueduct (VA) (n = 18). A total of 23 of 38 patients with JBVAD and 7 of 18 patients with close proximity of the JB and VA had hearing loss detected by audiometric evaluation. CONCLUSIONS: The most common hearing loss was detected as sensorineural hearing loss in patients with JBVAD. Also, median air and bone conduction and air bone gap values were found statistically higher in patients with hearing loss versus those without hearing loss.

Are Illness Perceptions Associated With Disease Activity or Psychological Well-Being in Rheumatoid Arthritis? A Study With the Evidence of Confirmatory Factor Analysis.

OBJECTIVES: This study aims to assess the factor structure of the Turkish Revised Illness Perception Questionnaire (IPQ-R) in patients with rheumatoid arthritis (RA) and the relationship of illness perceptions with disease activity and psychological well-being. PATIENTS AND METHODS: One hundred and fifty RA patients (8 males, 142 females; mean age 51.1±12.7 years; range 21 to 81 years) were included in the study. Confirmatory factor analysis was used to test the factor structure of the IPQ-R. Pain was assessed by visual analog scale, disease activity by Disease Activity Score 28, depression by Beck Depression Inventory, global life satisfaction by the Satisfaction with Life Scale, and illness perception by the IPQ-R. RESULTS: Three items (items 12, 18, 19) were deleted because of poor factor loadings. The modified 35-item model showed good reliability and discriminant validity. Beck Depression Inventory scores were correlated with identity, consequences, and emotional representations subscales positively (p<0.001); and with illness coherence subscale negatively (p<0.05). There were positive correlations between Satisfaction with Life Scale scores, and treatment control and illness coherence subscales (p<0.05). Satisfaction with Life Scale scores were negatively correlated with identity, emotional representation, and timeline acute/chronic subscales (p<0.05), and consequences subscale (p<0.001). Disease Activity Score 28 was not correlated with IPQ-R domains (p>0.05). CONCLUSION: The Turkish IPQ-R appears to be a useful clinical assessment tool to evaluate RA-related illness perceptions. RA healthcare should include psychological intervention to strengthen patients' beliefs about their RA regardless of disease activity.

Evaluation of the Posterior Tibial Slope in Noncontact ACL Injuries Using Magnetic Resonance Imaging.

This study investigated whether an increased posterior tibial slope (PTS) was a risk factor for noncontact anterior cruciate ligament (ACL) injuries. We retrospectively evaluated the Magnetic Resonance (MR) images of 60 patients with noncontact complete ruptures of the ACL and 60 age-matched, healthy individuals with normal knee MR images. We measured the medial and lateral PTS on the sagittal T1W images separately in both the patients with complete ACL ruptures and the control group, as described by Hudek et al. Medial and lateral PTS were investigated between two groups .The patients with complete ACL ruptures had a statistically significantly (p<0.01) larger PTS on the lateral tibial condyle than the control group (4.5° and 3.8°, respectively). However, there was no statistically significant differences between the two groups' medial PTS. Also, the lateral PTS was greater in the complete ACL group than the control group in both females and males (p<0.01).

Reliability and Validity of the Turkish Adaptation of VITACORA-19 in Patients with Psoriatic Arthritis.

OBJECTIVES: This study aims to evaluate the reliability and validity of the Turkish language version of VITACORA-19 (psoriatic arthritis quality of life questionnaire) in patients with psoriatic arthritis. PATIENTS AND METHODS: The Turkish version of VITACORA-19 questionnaire was obtained after a translation and back translation process. The study sample included 61 PsA patients (22 males, 39 females; mean age 46.5±12.2 years; range 19 to 71 years). To assess the test-retest reliability of the Turkish VITACORA-19, the questionnaire was reapplied 10 to 15 days after the first interview (interclass correlation coefficient). Cronbach's alpha (a) was used to evaluate the internal consistency. VITACORA-19 was compared with visual analog scale for physician and patient global assessments, the Health Assessment Questionnaire, and Nottingham Health Profile for construct validity. The internal structure of VITACORA-19 was examined by factor analysis. RESULTS: The individual item intraclass correlation coefficient ranged from 0.77 to 0.98 and Cronbach's alpha ranged from 0.77 to 0.98. The Cronbach's alpha value for whole scale was determined as 0.96. The Kaiser-Meyer-Olkin measure of sampling adequacy was 0.90, and Bartlett's test of sphericity had a p<0.001. Turkish VITACORA-19 total scores were correlated negatively with Health Assessment Questionnaire, visual analog scale for pain, and Nottingham Health Profile subgroups, and positively with physician and patient global assessments (p<0.01). CONCLUSION: Turkish version of VITACORA-19 questionnaire is a reliable and valid measure for health-related quality of life in Turkish patients with psoriatic arthritis.

The role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in exacerbation of chronic obstructive pulmonary disease.

OBJECTIVE: To investigate whether neutrophil-lymphocyte ratio and platelet-lymphocyte ratio like C-reactive protein can be used as markers of acute exacerbation in chronic obstructive pulmonary disease. METHODS: The cross-sectional study was conducted at Konya Training and Research Hospital, Konya, Turkey, between December 2012 and April 2013, and comprised patients with stable and acute chronic obstructive pulmonary disease. All participants were male and aged >40 years. Patients were included prospectively from outpatient and emergency units according to recent Initiative for Chronic Obstructive Lung Disease 2013 criteria. C-reactive protein, neutrophil-lymphocyte ratio and platelet-lymphocyte ratio of each group were measured and compared. RESULTS: Of the 94 patients, 48(51%) had stable disease with a mean age of 66.65±10.17 years (range: 49-79 years), and 46(49%) had acute exacerbation with a mean age of 62.67±9.41 years (range: 48-92 years). Mean levels of C-reactive protein, neutrophil-lymphocyte ratio and platelet-lymphocyte ratio were 5.04±6.65, 2.75±1.11 and 137.39±65.42 for stable disease, and 57.68±58.49, 7.99±5.72 and 231.18±141.36 for those with acute exacerbation (p=0.001). Cut-off values were neutrophil-lymphocyte ratio =3.3, platelet-lymphocyte ratio =150, and C-reactive protein =5 mg/dl. Positive predictive values for C-reactive protein, neutrophil-lymphocyte ratio and platelet-lymphocyte ratio were determined as 82% (odds ratio: 27.4); 85% (odds ratio: 32.5); and 73% (odds ratio: 6.3) . Receiver-operating characteristic curve showed a significantly more area under curve of neutrophil-lymphocyte ratio (0.88) compared to platelet-lymphocyte ratio (0.74) (p<0.05). CONCLUSIONS: During acute exacerbations of chronic obstructive pulmonary disease, neutrophil-lymphocyte ratio may be used as an easily measurable, available and cost-effective parameter with high prognostic accuracy in clinical practice.

Plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in psoriasis patients and correlation with disease severity.

OBJECTIVE: Psoriasis is a chronic, relapsing, inflammatory, hyper-proliferative skin disease. Plasma-soluble urokinase plasminogen activator receptor (suPAR) is released from the cell membrane-bound plasminogen activator and is a new biomarker of systemic inflammation. The aim of this study is to investigate plasma levels in psoriasis patients and determine their correlation with the Psoriasis Area and Severity Index (PASI) score. MATERIALS AND METHODS: The plasma suPAR levels of 50 healthy individuals and 65 psoriasis patients were measured using the Micro-ELISA method and the relation with PASI was investigated. RESULTS: On comparing plasma suPAR levels of the psoriasis patients with the control group consisting of healthy individuals, no statistically significant difference was determined (5.29 ng/ml ± 2.12 and 6.03 ng/ml ± 2.42, respectively, p = 0.326; Table 1). Likewise, there was no significant correlation between the suPAR levels and PASI score (r = 0.147, p = 0.243 > 0.05). CONCLUSION: There was no statistically significant difference in the plasma SuPAR levels of psoriasis patients compared to the control group. Nevertheless, we firmly believe that plasma SuPAR, a new biomarker, could indicate disease severity if conducted with larger patient series and with moderate to severe psoriasis patients.

Is the Mean Platelet Volume in Patients with Acute Cholecystitis an Inflammatory Marker?

INTRODUCTION: Acute cholecystitis is an inflammatory disease of the gallbladder. Ultrasonography (US) is the initial and the most valuable method in the diagnosis of acute cholecystitis. Also, laboratory findings are used to support the diagnosis. The aim of the present study was to evaluate the diagnostic value of mean platelet volume (MPV) and platelet (PLT) counts in patients with acute cholecystitis. MATERIALS AND METHODS: From January to August 2014, the medical records of patients were reviewed for the diagnosis of acute cholecystitis. The study included 60 age-matched patients with acute cholecystitis and 60 healthy individuals as a control group. Patients with a chronic disease were excluded from the study. Over all, patients with acute cholecystitis and patients in the control group were evaluated for their MPV, PLT count, platelet distribution width (PDW), platelet crit (PCT) and erythrocyte sedimentation rate (ESR) in a complete blood count (CBC). RESULTS: The MPV values were found to be significantly lower in the acute cholecystitis group when compared to the control group. The PDW and PCT were found to be significantly higher in the acute cholecystitis group when compered to the control group. When a correlation test was performed, MPV was negatively correlated with PLT and PCT counts. CONCLUSION: US is the initial and the most important imaging method for diagnosing and evaluating the biliary system. Also, laboratory findings such as WBC, ESR and CRP support the diagnosis but may have some undesirable limitations. However, MPV is an acute phase reactant that does not require an additional cost because it is already worked in the CBC. Therefore, MPV can be used as a marker in diagnosing inflammatory diseases.

(18)F-FDG PET/CT mean SUV and metabolic tumor volume for mean survival time in non-small cell lung cancer.

OBJECTIVE: The study was designed to determine the relationship between survival time of standardized uptake value (SUVmax and SUVmean) and metabolic tumor volume (MTV) in patients with non-small cell lung cancer (NSCLC), and examine the impact of demographic, clinical, and radiological data of these patients on survival. MATERIALS AND METHODS: We performed a retrospective analysis of the records of 79 patients with NSCLC who presented to our hospital between May 2010 and March 2013, received a final diagnosis, and underwent F-FDG PET/CT for staging. Clinical, radiological, and F-FDG PET/CT parameters with an impact on prognosis such as the SUVmax of the primary tumor as calculated by the volumetric region of interest in the F-FDG PET/CT scans during initial diagnosis, mean SUV of the tumor, and MTV obtained with a threshold of SUVmax greater than 2.5 were recorded and statistically analyzed. A statistical analysis was carried out based on the clinical, radiological, and PET/CT findings of the patients who were divided into 2 groups: survivors and nonsurvivors. RESULTS: Seventy patients (88.6%) were men, and 9 (11.4%) were women. The mean age was 63.65 ± 11.51 years in the nonsurvivor group (n = 40) versus 62.74 ± 10.60 years in the survivor group (n = 39) (Table 1). The mean survival time from diagnosis was 7.9 ± 6.52 months in the nonsurvivor group versus 14.09 ± 7.41 months in the survivor group. The mean survival time was 12.9 ± 7.9 months for those aged 60 or younger, whereas it was 9.9 ± 7.2 years for those aged 60 or older. According to the Cox regression analysis, higher MTV [relative risk (RR), 1.006; P = 0.03] and mean SUVmax (mSUV) (RR, 1.302; P = 0.03) had a significant impact on shortening of the mean survival time. However, no statistical significance was reached for SUVmax measurements (RR, 0.970; P = 0.39). Furthermore, there was a significant relationship between increased tumor size (<2 cm, 2-4 cm, and ≥4 cm) and shortened mean survival time (P = 0.03). CONCLUSION: The present study showed that MTV and mSUV of FDG PET/CT scans of the tumor, but not SUVmax, had a significant impact on survival time of patients with NSCLC. Based on this result, we believe that we might have more accurate information about the survival time of our patients if we also evaluate mSUV and MTV in combination with mSUV, which is frequently used for diagnosis and monitoring of patients with NSCLC during our daily practice.

Reliability of stool antigen tests: investigation of the diagnostic value of a new immunochromatographic Helicobacter pylori approach in dyspeptic patients.

BACKGROUND: A diagnosis of H. pylori infection can be made by invasive or non-invasive methods. Several noninvasive diagnostic tests based on the detection of H. pylori stool antigen (HpSA) have been developed. The Genx H. pylori stool antigen card test is a new rapid, non-invasive test that is based on monoclonal immunochromatographic assay. The aim of this study was to determine its sensitivity, specificity, and diagnostic accuracy for diagnosing H. pylori infection in adult patients. MATERIALS AND METHODS: A total of 162 patients were included in the study. A gastric biopsy was collected for histopathology and rapid urease testing. Stool specimens for HpSA testing were also collected. Patients were considered H. pylori positive if two invasive tests (histological and rapid urease tests) were positive. RESULTS: Using the reference test, 50.6% of the samples were positive for H. pylori infection. The Genx H. pylori antigen test was positive in 19.7% of patients. The sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of the Genx H. pylori antigen test were 51.6%, 96.0%, 88.8%, 76.1%, and 79.0%, respectively. CONCLUSIONS: The Genx H. pylori stool antigen card test is a new non-invasive method that is fast and simple to perform but provides less reliable results.

Assessment of evidence for positive association and seroprevalence of hepatitis B and C in diabetic patients in a developing country.

BACKGROUND AND AIM: The data related to the association between hepatitis virus infections and diabetes mellitus (DM) are conflicting. The aim of this study was to investigate the seroprevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) and to determine the risk factors affecting the prevalence in Turkish patients with type 1 DM and type 2 DM. METHODS: The study consisted of 736 diabetic and 505 nondiabetic patients. Serological investigation for the hepatitis B surface antigen (HBsAg) and the HCV antibody (anti-HCV) was performed with a third-generation commercial chemiluminescence assay. The presence of HBsAg was considered as indicator of HBV infection. The HCV infection in the patients with positive anti-HCV was confirmed by a real-time polymerase chain reaction assay. The patients were divided according to their HBV and HCV infection status, and their demographic features, diabetes properties, general risk factors, and aminotransferase levels were analyzed. RESULTS: There was no significant difference in the seropositivity rate for the HBsAg (3.8% vs 3.0%, P > 0.43; odds ratio, 1.292; 95% confidence interval, 0.683-2.444). However, anti-HCV seropositivity was significantly increased in the DM group (3.3% vs 1.8%, P < 0.03; odds ratio, 2.398; 95% confidence interval, 1.025-5.609). Increased aminotransferase levels and a history of blood transfusions were positively correlated with both HBV and HCV infection. Moreover, a history of surgical procedures and high glycated hemoglobin A1c levels were positively associated with HBsAg antigen seropositivity. CONCLUSIONS: Although no significant difference in the seropositivity of the HBsAg was determined, a high prevalence of HCV infection was detected in the DM patients compared to healthy controls.

Predicting survival for multiple myeloma patients using baseline neutrophil/lymphocyte ratio.

The neutrophil/lymphocyte ratio (NLR) at diagnosis has been shown to be a prognostic factor for survival in solid tumors. The NLR at diagnosis as a prognostic factor for multiple myeloma (MM) has not been studied. Therefore, the focus of the study was the correlation of NLR with the proven prognostic parameters in patients with MM. A total of 151 MM patients who fulfilled the International Myeloma Working Group (IMWG) criteria were enrolled in the study by a retrospective review of the patients' records. One hundred fifty-one age- and gender-matched healthy controls were also included in the study. NLR was calculated using data obtained from the complete blood count (CBC). NLR was significantly higher in MM patients than the control group (2.79 ± 1.82 vs. 1.9 ± 0.61, respectively; p < 0.0001). The median follow-up on living patients in this study was 41 months. NLR at the diagnosis was found to be an independent predictor for overall survival (OS) and event-free survival (EFS) by univariate and multivariate analysis. Patients with a NLR <2 at diagnosis experienced superior OS compared with patients with a NLR ≥2 (5-year OS rates were 87.5 and 42.4 %, respectively; p < 0.0001). In a similar fashion, superior EFS was observed in patients with a NLR <2 at the diagnosis compared with patients with a NLR ≥2 (5-year EFS rates were 88.4 and 41.8 %, respectively, p < 0.0001). This study suggests that NLR at the diagnosis is a simple, inexpensive, possible prognostic factor to assess clinical outcomes in MM patients.

Investigation of the relation between anaerobic bacteria genus clostridium and late-onset autism etiology in children.

The aim of this study was to investigate the relation between the etiology of late-onset childhood autism and anaerobic bacteria. Thirty children diagnosed with autistic disorder and control group have been included in the study. 3-(3-hydroxy phenyl)-3-hydroxypropionic acid (HPHPA) excretion rates which is a metabolic product of the genus Clostridium, were measured via mass spectrometry-gas chromatography (MS-GC) method from urine samples. When the assayed average HPHPA values compared with each group, a statistically significant difference was found (p < 0.05). Data obtained from this study support the existence of a significant correlation between autism etiology and anaerobic bacteria.

Comparison of the diagnostic accuracy of five different stool antigen tests for the diagnosis of Helicobacter pylori infection.

BACKGROUND: Several noninvasive diagnostic tests based on the detection of Helicobacter pylori stool antigen (HpSA) have been developed. The aim of the study was to compare the diagnostic accuracy of 5 HpSA tests-2 monoclonal enzyme immunoassay tests (EIAs: the Premier Platinum HpSA Plus test and Helicobacter pylori Antigen (Hp Ag) test) and 3 rapid immunochromatographic assay (ICA) tests (the ImmunoCard STAT! HpSA test, one step HpSA test, and H. pylori fecal antigen test)--for diagnosing H. pylori infection in adult patients with dyspeptic symptoms before eradication therapy. MATERIALS AND METHODS: A total of 198 patients with dyspeptic symptoms were included in the study. A gastric biopsy was collected for histopathology and rapid urease testing. Stool specimens for HpSA testing were also collected. Patients were considered H. pylori positive if two invasive tests (histological and rapid urease tests) were positive. RESULTS: The sensitivity and specificity were 92.2% and 94.4%, respectively, for the Premier Platinum HpSA Plus test; 48.9% and 88.9%, respectively, for the HP Ag test; 86.7% and 88.9, respectively, for the One Step HpSA test; 68.9% and 92.6%, respectively, for the ImmunoCard STAT! HpSA test; and 78.9% and 87%, respectively, for the H. Pylori fecal antigen test. CONCLUSIONS: The Premier Platinum HpSA Plus EIA test was determined to be the most accurate stool test for diagnosing H. pylori infections in adult dyspeptic patients. The currently available ICA-based tests are fast and easy to use but provide less reliable results.